171 related articles for article (PubMed ID: 35488386)
41. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
Samon JB; Castillo-Martin M; Hadler M; Ambesi-Impiobato A; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Jakubczak J; Randolph S; Cordon-Cardo C; Ferrando AA
Mol Cancer Ther; 2012 Jul; 11(7):1565-75. PubMed ID: 22504949
[TBL] [Abstract][Full Text] [Related]
42. Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia.
Kumar V; Palermo R; Talora C; Campese AF; Checquolo S; Bellavia D; Tottone L; Testa G; Miele E; Indraccolo S; Amadori A; Ferretti E; Gulino A; Vacca A; Screpanti I
Leukemia; 2014 Dec; 28(12):2324-35. PubMed ID: 24727676
[TBL] [Abstract][Full Text] [Related]
43. Recent advances on NOTCH signaling in T-ALL.
Tzoneva G; Ferrando AA
Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
[TBL] [Abstract][Full Text] [Related]
44. Differentiation of primordial germ cells from induced pluripotent stem cells of primary ovarian insufficiency.
Leng L; Tan Y; Gong F; Hu L; Ouyang Q; Zhao Y; Lu G; Lin G
Hum Reprod; 2015 Mar; 30(3):737-48. PubMed ID: 25586786
[TBL] [Abstract][Full Text] [Related]
45. Deciphering the heterogeneity in DNA methylation patterns during stem cell differentiation and reprogramming.
Shao X; Zhang C; Sun MA; Lu X; Xie H
BMC Genomics; 2014 Nov; 15(1):978. PubMed ID: 25404570
[TBL] [Abstract][Full Text] [Related]
46. Inducing pluripotency in vitro: recent advances and highlights in induced pluripotent stem cells generation and pluripotency reprogramming.
Rony IK; Baten A; Bloomfield JA; Islam ME; Billah MM; Islam KD
Cell Prolif; 2015 Apr; 48(2):140-56. PubMed ID: 25643745
[TBL] [Abstract][Full Text] [Related]
47. Identification of New Transcription Factors that Can Promote Pluripotent Reprogramming.
Huang P; Zhu J; Liu Y; Liu G; Zhang R; Li D; Pei D; Zhu P
Stem Cell Rev Rep; 2021 Dec; 17(6):2223-2234. PubMed ID: 34448118
[TBL] [Abstract][Full Text] [Related]
48. Excluding Oct4 from Yamanaka Cocktail Unleashes the Developmental Potential of iPSCs.
Velychko S; Adachi K; Kim KP; Hou Y; MacCarthy CM; Wu G; Schöler HR
Cell Stem Cell; 2019 Dec; 25(6):737-753.e4. PubMed ID: 31708402
[TBL] [Abstract][Full Text] [Related]
49. Reprogramming and differentiation-dependent transcriptional alteration of DNA damage response and apoptosis genes in human induced pluripotent stem cells.
Shimada M; Tsukada K; Kagawa N; Matsumoto Y
J Radiat Res; 2019 Nov; 60(6):719-728. PubMed ID: 31665364
[TBL] [Abstract][Full Text] [Related]
50. Generation of two induced pluripotent stem cells lines from a Mucopolysaccharydosis IIIB (MPSIIIB) patient.
Vallejo-Diez S; Fleischer A; Martín-Fernández JM; Sánchez-Gilabert A; Bachiller D
Stem Cell Res; 2018 Dec; 33():180-184. PubMed ID: 30408744
[TBL] [Abstract][Full Text] [Related]
51. The Effects of
Liu H; Liu Z; Gao M; Hu X; Sun R; Shen X; Liu F; Shen J; Shan Z; Lei L
Cell Reprogram; 2020 Apr; 22(2):90-98. PubMed ID: 32150692
[TBL] [Abstract][Full Text] [Related]
52. Nanog-independent reprogramming to iPSCs with canonical factors.
Carter AC; Davis-Dusenbery BN; Koszka K; Ichida JK; Eggan K
Stem Cell Reports; 2014 Feb; 2(2):119-26. PubMed ID: 24527385
[TBL] [Abstract][Full Text] [Related]
53. Development of the
Li Z; Chen X; Liu L; Zhou M; Zhou G; Liu T
Med Oncol; 2022 Sep; 39(12):200. PubMed ID: 36173527
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.
Palomero T; Ferrando A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S205-10. PubMed ID: 19778842
[TBL] [Abstract][Full Text] [Related]
55. A Serial shRNA Screen for Roadblocks to Reprogramming Identifies the Protein Modifier SUMO2.
Borkent M; Bennett BD; Lackford B; Bar-Nur O; Brumbaugh J; Wang L; Du Y; Fargo DC; Apostolou E; Cheloufi S; Maherali N; Elledge SJ; Hu G; Hochedlinger K
Stem Cell Reports; 2016 May; 6(5):704-716. PubMed ID: 26947976
[TBL] [Abstract][Full Text] [Related]
56. Long-range enhancer activity determines Myc sensitivity to Notch inhibitors in T cell leukemia.
Yashiro-Ohtani Y; Wang H; Zang C; Arnett KL; Bailis W; Ho Y; Knoechel B; Lanauze C; Louis L; Forsyth KS; Chen S; Chung Y; Schug J; Blobel GA; Liebhaber SA; Bernstein BE; Blacklow SC; Liu XS; Aster JC; Pear WS
Proc Natl Acad Sci U S A; 2014 Nov; 111(46):E4946-53. PubMed ID: 25369933
[TBL] [Abstract][Full Text] [Related]
57. Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer's disease donor as a model for investigating AD-associated gene regulatory networks.
Hossini AM; Megges M; Prigione A; Lichtner B; Toliat MR; Wruck W; Schröter F; Nuernberg P; Kroll H; Makrantonaki E; Zouboulis CC; Adjaye J
BMC Genomics; 2015 Feb; 16(1):84. PubMed ID: 25765079
[TBL] [Abstract][Full Text] [Related]
58. New insights into the genic and metabolic characteristics of induced pluripotent stem cells from polycystic ovary syndrome women.
Min Z; Gao Q; Zhen X; Fan Y; Tan T; Li R; Zhao Y; Yu Y
Stem Cell Res Ther; 2018 Aug; 9(1):210. PubMed ID: 30092830
[TBL] [Abstract][Full Text] [Related]
59. Generation of Human iPSCs by Episomal Reprogramming of Skin Fibroblasts and Peripheral Blood Mononuclear Cells.
Febbraro F; Chen M; Denham M
Methods Mol Biol; 2021; 2239():135-151. PubMed ID: 33226617
[TBL] [Abstract][Full Text] [Related]
60. Immortalized prairie vole-derived fibroblasts (VMF-K4DTs) can be transformed into pluripotent stem cells and provide a useful tool with which to determine optimal reprogramming conditions.
Katayama M; Hirayama T; Kiyono T; Onuma M; Tani T; Takeda S; Nishimori K; Fukuda T
J Reprod Dev; 2017 Jun; 63(3):311-318. PubMed ID: 28331164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
